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Abstract
Background: ‘Virtual’ or inferred phenotypes (vPhenotypes) are commonly used to assess resistance to antiretroviral agents
in patients failing therapy. In this study, we provide a clinical context for understanding vPhenotype values.
Methods: All HIV-infected persons enrolled in the British Columbia Drug Treatment Program with a baseline plasma viral
load (pVL) and follow-up genotypic resistance and pVL results were included up to October 29, 2008 (N = 5,277). Change
from baseline pVL was determined as a function of Virco vPhenotype, and the ‘‘dynamic range’’ (defined here by the 10th
and 90th percentiles for fold-change in IC50 amongst all patients) was estimated from the distribution of vPhenotye fold-
changes across the cohort.
Results: The distribution of vPhenotypes from a large cohort of HIV patients who have failed therapy are presented for all
available antiretroviral agents. A maximum change in IC50 of at least 13-fold was observed for all drugs. The dideoxy drugs,
tenofovir and most PIs exhibited small ‘‘dynamic ranges’’ with values of ,4-fold change observed in .99% of samples. In
contrast, zidovudine, lamivudine, emtricitabine and the non-nucleoside reverse transcriptase inihibitors (excluding
etravirine) had large dynamic ranges.
Conclusion: We describe the populational distribution of vPhenotypes such that vPhenotype results can be interpreted
relative to other patients in a drug-specific manner.
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Introduction
HIV drug resistance testing assists clinical decision-making in
the selection of antiretroviral therapy [1,2], and is routinely used
as a guide to future treatment options for HIV-infected patients
who develop virological treatment failure [3,4]. A number of
genotypic resistance interpretation systems are available based on
either rules-based algorithms or ‘‘virtual phenotypes.’’ However,
the lack of concordance (up to ,20%, [5]) among the data
generated using these systems clearly signals a need for
standardization and a context from which to approach an
individual patient’s result [6].
Currently, genotypic rather than phenotypic tests are commonly
used for drug resistance testing, largely due to the former’s lower
cost and faster turn-around time. However, inferring phenotypes
from genotypic testing remains a challenge due to subtle changes
in viral replication and patterns of mutational profiles. Conse-
quently, the various genotype-phenotype interpretation algorithms
have met with variable success [1,7,8,9].
Cut-offs
The interpretation of either a virtual or real phenotype is based
primarily on a ‘‘cut-off’’ value, which defines a threshold between
a susceptible wild-type phenotype and a reduced drug suscepti-
bility (ie, resistant) phenotype. Initially, cut-offs were based on the
reproducibility of the assay (‘‘technical cutoffs’’). With this system,
all antiretrovirals were assigned the same (relatively arbitrary) cut-
off value, and if the fold-change in drug concentration required to
inhibit the virus was greater than this value, the variants were
considered to have reduced susceptibility compared to wild type.
This was subsequently refined by the use of epidemiologically
derived cut-offs from the distribution of wild-type susceptibilities in
large numbers of antiretroviral-naı¨ve patients [10]. These
biological cut-offs take advantage of the natural variation in drug
susceptibility present in non-drug-exposed HIV variants [10] and
are more clinically relevant than arbitrary values for assay
reproducibility. However, biological cut-offs are not derived from
data of clinical responses to antiretroviral agents and may
therefore lack clinical relevance.
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In a phenotypic resistance assay, the degree of resistance is
defined using the median inhibitory concentration (IC50). IC50 is the
concentration of a drug required for a 50% inhibition of viral
replication in vitro [11]. vPhenotypes are assembled using large
databases of phenotypic resistance data matched to genotypic viral
sequences derived from patients. The resistance level of a
vPhenotype is based on observed phenotypic fold-changes (FC) in
IC50 associated with the replication of a virus with a given sequence.
Higher fold-changes represent lower susceptibility to the drug
relative to the reference strain. In other words, if a virus showed a
two-fold increase in IC50 (essentially a vPhenotype value of 2), this
would indicate that twice as much drug would be required to inhibit
viral replication by one-half, compared to a wild-type virus. Thus,
the phenotypic resistance level of a patient’s virus can be predicted
from the vPhenotype associated with the viral sequence.
However, cut-offs based on the actual in vivo virological response
to a regimen may better inform the interpretation of resistance
data [12] and may provide a more accurate clinical prognosis for
patients on long-term antiretroviral therapy. Clinical cut-offs
(CCO) can be established by using vPhenotypes to determine
clinically relevant phenotypic fold-change resistance levels [13]. In
this approach, the cutoffs are defined not by an in vitro indicator,
but by actual virologic responses to therapy in patients with drug
resistant HIV. The lower CCO indicates the point at which
virologic response to an agent begins to be compromised, and the
upper CCO indicates the point where response to the agent is
nearly completely abolished [13].
In addition to knowing whether a patient’s inferred phenotype is
above or below a given clinical or biological cut-off, we feel that it
may be useful to place the results against the spectrum of other
patients experiencing virological treatment failure. By comparing
vPhenotype levels across such a dataset, frequency distributions of
the various resistance levels may be constructed, revealing a profile
of the resistance generally experienced by patients during drug
treatment. This serves as a good point of comparison for assessing
the severity of a patient’s vPhenotypic resistance level in the
context of other patients undergoing treatment. By combining all
patient-derived resistance data together, the drug’s overall
‘‘dynamic range’’ can be determined as the range of vPhenotype
scores between which a majority of patient samples fall.
Here we present data on the distribution of vPhenotypes from a
large cohort of patients failing therapy in British Columbia,
Canada. We have determined minimum and maximum virtual
phenotypic susceptibility, as well as the ‘‘dynamic range’’ of
susceptibility for all licensed antiretroviral agents.
Methods
Study population
We evaluated all HIV-infected adults who enrolled in the British
Columbia (BC) Drug Treatment Program between 1996 and 2008
with a baseline plasma viral load (pVL) .1000 HIV RNA copies/
mL until 2001 and .250 copies/mL thereafter; and for whom at
least one follow-up sample with genotypic drug resistance data was
available. Samples were evaluated from a total of 5,277 patients,
most of whom had multiple samples (median 2; inter-quartile range:
1–5). From these samples, a total of 19,611 vPhenotype results were
obtained by genotyping of the HIV protease (PR) and reverse
transcriptase (RT) regions for HIV drug resistance mutations at the
BC Centre for Excellence in HIV/AIDS.
HIV RNA extraction and drug resistance analysis
Drug resistance testing was performed on physician-requested
samples with pVL as defined above. HIV RNA was extracted from
frozen plasma samples using guanidinium-based lysis buffer
followed by isopropanol/ethanol washes or by automated
extraction using a NucliSENS easyMAG (bioMerieux). Amplifi-
cation of the PR and RT regions was performed using nested RT-
PCR and sequenced in both the 59 and 39 directions on an ABI
3100 or 3730 automated sequencer. Sequence data were analyzed
using Sequencher (Genecodes) or RE_Call (BC Centre for
Excellence in HIV/AIDS [14,15,16]) sequencing software.
Nucleotide mixtures were identified if the secondary peak height
exceeded 20% of the dominant peak height. Sequences were
aligned to HIV-1 subtype B reference strain HXB2 (Genbank Acc.
No. K03455) using a modified NAP algorithm [17]. Results of the
genotyping analysis were reported as amino acid changes in the
HIV protease and reverse transcriptase genes relative to HXB2.
Generation and analysis of vPhenotypes
Virco (Mechelen, Belgium) converted the genotypic sequence
data to Virtual Phenotypes. The vircoHTYPE versions used in this
analysis varied over time, where the specific version used
depended on the version in place at the time of testing.
vPhenotype results were expressed as percentile ranks of fold-
change in IC50 for each antiretroviral drug. Analysis of the
distribution of vPhenotypes was performed on two groups: all
samples sequenced within the BC Drug Treatment program
(N = 19,611), and a subset of about half of these samples
(N = 9,606) which had one or more International AIDS Society
(IAS) key drug resistance mutation(s) [18]. The dynamic range of
vPhenotype scores for each agent was defined as the range
between 10th and 90th percentiles of values. These percentiles were
somewhat arbitrarily chosen, but are illustrative in that they reflect
the range between which a majority of patient samples falls, while
excluding outlier values. We have also presented the 1st & 99th,
and 5th & 95th percentiles for the reader’s convenience.
Ethics Statement
Ethical approval was granted by the Providence Health Care/
University of British Columbia Ethics Board. All data were
analysed anonymously. Requirement for consent was waived by
the Ethics Board because the analysis involved no more than
minimal risk to subjects.
Results
Distribution of virtual phenotypes
Virtual phenotypes were collected for a total of 19,611 samples
from 5,277 different patients. Results were analyzed in two sets: (I)
all samples submitted for virtual phenotyping; and (II) a subset of
group I for which at least one key IAS resistance mutation [18]
was identified. The distribution of vPhenotypes for all samples
tested in BC is summarized in Table 1. The distribution of
vPhenotypes for samples with one or more IAS key mutation
(N = 9,606) is shown for each drug class in Figures 1, 2, and 3, and
summarized in Table 2. Overall, the shapes of the distributions
from both groups resemble each other closely within each drug
class. Data are generally presented for the IAS key mutation subset
for simplicity, to limit the effect of testing of antiretroviral-naı¨ve
individuals, as well as to emphasize a more clinically relevant
group of patients where at least some degree of drug resistance is
certain.
Also shown for each drug is the proportion of patients (with 1 or
more IAS resistance mutation) that fall below, between, and above
the clinical cut-offs of the Virco vPhenotype reports (Table 3). In
general, a majority of these patients have virus that falls below the
lower clinical cut off (CCO) for most drugs that have established
Distribution of vPhenotypes
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CCOs: 15/19 drugs (79%). The exceptions are the nucleoside
reverse transcriptase inhibitors lamivudine (3TC), emtricitabine
(FTC), didanosine (ddI), and abacavir (ABC), with the former two
having a majority of patients with vPhenotypes above the upper
CCO, and the latter two with a majority of patients falling
between the two CCOs. When all 19,611 vPhenotypes were
examined, a majority of samples had vPhenotypes below the lower
CCO for every agent except ddI (data not shown).
It is worth noting that HIV from patients exhibited a range of
‘‘wild-type’’ phenotypic susceptibility to different drugs that was
above or below that seen for the reference laboratory wild-type
strain. In other words, the baseline drug susceptibility of ‘‘wild-
type’’ viruses varied among different patient-derived HIV strains,
and this range of baseline susceptibility should be kept in mind
when considering the susceptibility of resistant viruses. For
example, the 50th percentile for vPhenotypes of most drugs
hovered around 1-fold change (0.6 to 1.6), but with two notable
exceptions of .40-fold change for 3TC and FTC (Table 2).
Fold-change in IC50 was .1 in a majority of non-nucleoside
reverse transcriptase inhibitor (NNRTI) samples and ,1 in more
than 50% of protease inhibitor (PI) and nucleoside reverse
transcriptase inhibitor (NRTI) samples (Table 1 and 2). The
range and pattern of vPhenotype distribution varied widely among
the different antiretrovirals. Stavudine (d4T), didanosine (ddI), and
tenofovir (TDF) displayed some of the lowest maximum changes in
vPhenotype susceptibilities (approximately 13- to 25-fold, Table 1)
and the narrowest ‘‘dynamic ranges,’’ all falling between 0.7- and
1.8-fold (Table 1). For these drugs there was a modest ,2-fold
decrease in susceptibility in 90% of samples and ,4-fold decrease
in susceptibility in 99% of all samples tested. In contrast, the
NNRTIs delavirdine (DLV) and nevirapine (NVP) exhibited the
broadest dynamic ranges of approximately 1- to 60-fold. The
maximum fold-change in IC50 for any drug was not representative
of the drug’s dynamic range. For the drugs studied, the median
difference was ,12-fold between the maximum decrease in
susceptibility and the upper limit of the dynamic range, with this
difference being most dramatic for the NNRTIs (Table 1).
NRTIs. Overall, there are three general distributions of
resistance within the NRTI class: 3TC/FTC comprise one
group; zidovudine (AZT) comprises another; and the remaining
NRTIs (ddI, d4T, TDF, and ABC) comprise a third group
(Figure 1). 3TC and FTC both displayed the broadest dynamic
ranges, reaching approximately 50-fold decreased susceptibility
(more than 10 times greater than the upper limit of dynamic range
observed for the other NRTIs, excepting AZT). AZT exhibited an
intermediate dynamic range, while the other NRTIs showed a
relatively narrow range of resistance.
NNRTIs. Two distinct groupings of NNRTI drugs were
observed based on the distribution of virtual phenotypes: etravirine
(ETR), the newest member of this drug class, constituted one
Table 1. HIV susceptibility to antiretroviral agents (All BC vPhenotypes).
Probability distribution of Virtual phenotype (fold-change in IC50)
(N=19,611)
Drug
Lower CCO –
Upper CCO N Percentile
Min 1st 5th 10th 50th 90th 95th 99th Max
AZT 1.5–11.4 18392 0.4 0.7 0.8 0.9 1.1 11.3 19.6 41.2 105
3TC 1.2–4.6 18432 0.7 0.8 0.9 0.9 1.0 48.4 50.6 57.5 133.8
ddI 0.9–2.6 18177 0.6 0.8 0.8 0.8 0.9 1.7 2.2 2.7 24.4
d4T 1.0–2.3 18281 0.5 0.7 0.7 0.7 0.9 1.4 1.7 2.8 13.3
ABC 0.9–3.5 18135 0.5 0.7 0.7 0.7 0.8 3.2 4.0 5.4 22.4
FTC 3.1* 7915 0.5 0.6 0.7 0.7 0.8 47.5 50.2 52.6 82.6
TDF 1.0–2.3 13799 0.4 0.6 0.6 0.7 0.8 1.5 2.1 3.3 18.2
NVP 6.0* 18538 0.5 1.0 1.2 1.2 1.4 58.0 64.1 76.1 2152.5
DLV N/A 16624 0.3 1.3 1.3 1.3 1.6 60.9 109.6 151.4 224.5
EFV 3.3* 18491 0.3 0.9 1.0 1.0 1.1 24.9 105.8 316.3 43341.0
ETR 1.6–27.6 1545 0.3 0.4 0.7 0.8 1.2 2 4.2 22.8 460.0
IDV/r 2.3–27.2 18335 0.2 0.6 0.7 0.7 0.7 2.2 11.6 29.7 145.7
RTV N/A 16498 0.3 0.7 0.7 0.7 0.8 4.1 32.8 111.5 258.3
NFV 1.2–9.4 18325 0.4 0.8 0.9 0.9 0.9 6.5 24.2 41.2 115.6
SQV/r 3.1–22.6 18355 0.3 0.5 0.6 0.6 0.7 1.2 6.9 39.9 183.9
FPV/r 1.5–19.5 6631 0.2 0.5 0.6 0.6 0.6 0.8 1.2 17.2 121.5
LPV/r 6.1–51.2 16293 0.4 0.7 0.7 0.8 0.8 1.0 3.4 62.0 298.4
ATV/r 2.5–32.4 8559 0.5 0.6 0.6 0.7 0.7 0.9 1.5 76.9 303.8
TPV/r 1.5–7.0 6566 0.3 0.6 0.7 0.7 0.8 0.9 1.0 2.4 29.2
DRV/r 10.0–106.9 1853 0.3 0.4 0.5 0.5 0.6 0.7 0.8 2.7 20.9
Dynamic range indicated by italics.
*A total of 3 drugs have only one biological cut-off (for in vitro susceptibility): FTC, NVP, and EFV.
AZT – zidovudine, 3TC – lamivudine; ddI – didanosine; d4T – stavudine; ABC – abacavir; FTC – emtricitabine; TDF – tenofovir; NVP – nevirapine; DLV – delavirdine; EFV –
efavirenz; ETR – etravirine; /r – ritonavir boosted; IDV – indinavir; RTV – ritonavir; NFV – nelfinavir; SQV – saquinavir; FPV – fosamprenavir; LPV – lopinavir; ATV –
atazanavir; TPV – tipranavir; DRV – darunavir.
doi:10.1371/journal.pone.0017402.t001
Distribution of vPhenotypes
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Figure 1. Distribution of Resistance to NRTIs (BC vPhenotypes with 1 or More IAS Key Mutation). The distribution of the vPhenotype
value (log transformed) for nucleoside/nucleotide reverse transcriptase inhibitors across samples tested in British Columbia where at least 1
International AIDS Society key mutation was present. Percentiles indicated include every half percentile, as the minimum and maximum values for
each agent. AZT = zidovudine, 3TC = lamivudine, ddI = didanosine, d4T = stavudine, ABC = abacavir, FTC = emtricitabine, TDF = tenofovir. The
individual distributions may be grouped into 3 general categories: 3TC/FTC, AZT, and other NRTIs.
doi:10.1371/journal.pone.0017402.g001
Figure 2. Distribution of Resistance to NNRTIs (BC vPhenotypes with 1 or More IAS Key Mutation). The distribution of the vPhenotype
value (log transformed) for non-nucleoside reverse transcriptase inhibitors across samples tested in British Columbia where at least 1 International
AIDS Society key mutation was present. Percentiles indicated include every half percentile, as the minimum and maximum values for each agent.
Note that the scale of the horizontal axis extends to 1000 rather than 100 for Figures 1a and 1c, reflecting the higher maximum fold-change values
observed for the NNRTI drug class. NVP = nevirapine, DLV = delavirdine, EFV = efavirenz, ETR = etravirine.
doi:10.1371/journal.pone.0017402.g002
Distribution of vPhenotypes
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group, while all other NNRTIs (efavirenz [EFV], delavirdine
[DLV] and nevirapine [NVP]) comprised the second. ETR
exhibited a dynamic range roughly similar to that of the third
group of nucleoside agents discussed above (i.e., ddI, d4T, ABC,
TDF), while the other NNRTIs displayed dynamic ranges
approximately 10 times wider (Table 2, Figure 2). In general,
the NNRTIs (excluding ETR) had the widest dynamic ranges of
susceptibility and the largest maximum fold-changes in IC50 (over
40,000-fold for EFV) of all the drugs studied.
PIs. The protease inhibitors all exhibited roughly the same
dynamic ranges and distributions of resistance (Tables 1 and 2,
Figure 3). Most fell within a relatively narrow dynamic range of
,1-fold to approximately 7-fold, though ritonavir (RTV) and
nelfinavir (NFV) exhibited larger dynamic ranges extending to
.20-fold. Indinavir (IDV) displayed an intermediate dynamic
range with an upper limit of 11.6-fold (Table 2). The dynamic
ranges of tipranavir (TPV) and darunavir (DRV) were especially
low (0.7 to 1.0; and 0.5 to 1.0, respectively), indicating that almost
90% of patient virus in BC was hypersusceptible to these agents –
though fewer patients in our program have been treated with them
(Tables 1 and 2). For all PIs, the median fold-change in
susceptibility was #1, indicating a majority of samples having
lower susceptibility to these agents compared to the reference
strain.
Comparing the dynamic range of vPhenotypes to clinical
cutoffs
The ‘‘dynamic range’’ for most NRTIs was generally compa-
rable to the range between their individual CCOs, with the
exception of zidovudine and lamivudine, where the 90th percentile
was well above the upper Virco CCO. Conversely, the dynamic
ranges of most PIs (excluding nelfinavir) were well within the range
of their CCOs, perhaps reflecting the higher genetic barrier to
resistance for this drug class. Neither of the two most common
NNRTIs nevirapine nor efavirenz has a defined CCO range, so
the NNRTIs are excluded from this comparison.
Discussion
Here we present the distribution of vPhenotypes from a large
cohort of HIV-infected individuals who initiated antiretroviral
therapy in British Columbia between 1996 and 2008 and who
subsequently failed antiretroviral therapy during follow-up. These
data clearly indicate that the range of IC50 values varies widely
among antiretroviral agents regardless of drug class. For example,
the upper limit of the dynamic range (90th percentile) varied from
1-fold change for the PIs TPV and DRV to around 100 for the
NNRTIs DLV and EFV. The maximum fold-change in IC50
varied even more dramatically, ranging from approximately 13 for
d4T to more than 43,000 for EFV. Some sequences exceeded the
upper limits of the assay’s ability to measure vPhenotype. The
wide variability in IC50 fold-change also points to the value of
interpreting variations in susceptibility within the context of a large
dataset of other patient samples, such as that described here. We
also present the proportion of patients with HIV that falls between
and outside the Virco clinical cut-offs for vPhenotype resistance,
which provides a good basis for the overall extent of drug
resistance to various antiretroviral agents in a typical Western
clinical setting.
A raw FC-IC50 vPhenotype score is difficult to interpret and is
unlikely to be useful clinically, as its meaning may vary depending
on the drug under consideration. Interpreting the vPhenotype of a
patient-derived virus in the context of other patients’ viruses may
be more useful. For example, an IC50 change of 15-fold would be
within the expected dynamic range for most NNRTIs, but would
Figure 3. Distribution of Resistance to PIs (BC vPhenotypes with 1 or More IAS Key Mutation). The distribution of the vPhenotype value
(log transformed) for protease inhibitors across samples tested in British Columbia where at least 1 International AIDS Society key mutation was
present. Percentiles indicated include every half percentile, as the minimum and maximum values for each agent. IDV = indinavir, RTV = ritonavir,
NFV = nelfinavir, SQV = saquinavir, FPV = fosamprenavir, ATV = atazanavir, TPR = tipranavir, DRV = darunavir, LPV = lopinavir.
doi:10.1371/journal.pone.0017402.g003
Distribution of vPhenotypes
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be considered exceptionally resistant if it applied to tenofovir.
Further, since a majority of vPhenotypes collected fell below the
lower Virco clinical cut-off defined for each drug, it may be
additionally helpful to examine the distribution of vPhenotypes
within a population in order to better resolve differences in
resistance amongst patients. This approach may be especially
useful in the case of newly released drugs, where clinical outcome
data associated with the vPhenotypes are unknown.
A drug’s vPhenotypic dynamic range provides a useful
framework for interpreting vPhenotypic resistance data and
captures information about the population distribution for
resistance, which may also be useful. Note however, that its
relevance for patient outcomes is not known and that the dynamic
range of a drug may not necessarily reflect its clinical utility. 3TC/
FTC susceptibility is dramatically decreased by a single mutation
(the M184V mutation in reverse transcriptase [19]), giving a large
dynamic range. Nevertheless, these are very effective, commonly
prescribed agents. Similarly, there is no direct link between
dynamic range and clinical outcomes for the PI drug class, since
boosted-PI therapy is associated with better outcomes than
treatment with non-boosted PIs, even though the patient’s virus
exhibits the same vPhenotype value for both.
The prevalence of resistance to specific drugs among patients
failing therapy in our cohort largely reflects local prescription
patterns over the past decade, as well as the introduction of new
drugs over the years [20]. This also had an effect on the number of
samples exposed to different drugs, with many samples
(N = 18,392 of the total 19,611) exposed to the first antiretroviral
drug, AZT, but fewer for recently approved drugs such as ETR
(N = 1,545). Also playing a role are single-mutations that confer
drug resistance, such as is seen for 3TC/FTC and the M184V
mutation [20]. Drug resistance patterns as a whole also changed
over time, with fewer cases of resistance in more recent years [21].
In addition, the specific Virco vPhenotype version has also
changed over time, which may have influenced our results (though
in general, the ranges were similar for all two year periods from
2000 to 2008, with the main exceptions of lopinavir and
atazanavir, reflecting the introduction of widespread use of these
agents; Figures S1, S2, S3).
The maximum changes in IC50 observed here were generally
lower than those reported for ‘‘real’’ phenotypes determined using
a recombinant viral assay (Virco AntivirogramH [22]). This is
mainly due to the fact that a virtual phenotype is an average of
fold-changes in IC50 seen in database samples with similar
mutational profiles, while the actual phenotype assay will give a
physical result of the ability of the virus to grow in the presence of
a drug.
These data have enabled us to generate the range of phenotypes
for each antiretroviral agent into which the vast majority of HIV
patients receiving treatment in British Columbia will fall. As such,
Table 2. HIV susceptibility to antiretroviral agents (All BC vPhenotypes with one or more IAS Key mutation).
Probability distribution of Virtual phenotype (fold-change in IC50)
(N=9,606)
Drug
Lower CCO –
Upper CCO N Percentile
Min 1st 5th 10th 50th 90th 95th 99th Max
AZT 1.5–11.4 9360 0.4 0.7 0.8 0.8 1.3 19.5 27.5 52.7 105
3TC 1.2–4.6 9402 0.8 0.9 0.9 0.9 45.8 50.5 51.7 58.2 133.8
ddI 0.9–2.6 9149 0.6 0.8 0.8 0.8 1.2 2.2 2.5 3.5 24.4
d4T 1.0–2.3 9251 0.5 0.7 0.7 0.7 0.9 1.7 2.2 4.4 13.3
ABC 0.9–3.5 9105 0.6 0.7 0.7 0.7 1.6 4.0 4.9 6.5 22.4
FTC 3.1* 2829 0.6 0.7 0.7 0.8 41.8 50.9 52.1 54.1 82.6
TDF 1.0–2.3 6435 0.4 0.6 0.6 0.6 0.9 2.1 2.5 3.8 18.2
NVP 6.0* 9513 0.5 1.1 1.2 1.3 1.4 64.0 69.6 83.0 2152.5
DLV N/A 8866 0.3 1.3 1.3 1.5 1.6 100.0 141.3 158.3 224.5
EFV 3.3* 9468 0.3 0.9 1.0 1.1 1.2 94.8 181.1 411.0 43341.0
ETR 1.6–27.6 500 0.3 0.3 0.5 0.6 1.2 8.2 11.9 60.8 460.0
IDV/r 2.3–27.2 9303 0.2 0.7 0.7 0.7 0.8 11.6 19.5 37.8 145.7
RTV N/A 8733 0.3 0.7 0.7 0.7 0.8 29.5 59.3 160.9 258.3
NFV 1.2–9.4 9293 0.4 0.8 0.9 0.9 1.0 24.1 34.2 44.4 115.6
SQV/r 3.1–22.6 9323 0.3 0.4 0.6 0.6 0.7 6.9 29.4 42.8 183.9
FPV/r 1.5–19.5 2290 0.2 0.5 0.6 0.6 0.6 2.4 6.1 27.6 121.5
LPV/r 6.1–51.2 7707 0.4 0.7 0.7 0.8 0.8 4.6 22.1 86.2 298.4
ATV/r 2.5–32.4 3071 0.5 0.6 0.7 0.7 0.7 7.1 42.1 97.3 303.8
TPV/r 1.5–7.0 2232 0.3 0.5 0.7 0.7 0.8 1.0 1.4 9.0 29.2
DRV/r 10.0–106.9 586 0.3 0.4 0.5 0.5 0.6 1.0 1.9 10.5 20.9
Dynamic range indicated by italics.
*A total of 3 drugs have only one biological cut-off (for in vitro susceptibility): FTC, NVP, and EFV.
AZT – zidovudine, 3TC – lamivudine; ddI – didanosine; d4T – stavudine; ABC – abacavir; FTC – emtricitabine; TDF – tenofovir; NVP – nevirapine; DLV – delavirdine; EFV –
efavirenz; ETR – etravirine; /r – ritonavir boosted; IDV – indinavir; RTV – ritonavir; NFV – nelfinavir; SQV – saquinavir; FPV – fosamprenavir; LPV – lopinavir; ATV –
atazanavir; TPV – tipranavir; DRV – darunavir.
doi:10.1371/journal.pone.0017402.t002
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we believe this approach provides an objective framework for
interpreting drug resistance that puts all drugs within a clinically
relevant context and allows for the establishment of standardized
guidelines for the application of drug resistance data in clinical
practice. Although the data presented here represent a time-
dependent phenomenon that reflects the standard of HIV care in
British Columbia, these data could be regularly updated and this
approach could provide a new avenue of analysis for international
data.
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